Ac Immune Sa (ACIU)

$3.65

+0.17

(+4.74%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $3.46
    $3.65
    $3.65
    downward going graph

    5.21%

    Downside

    Day's Volatility :5.21%

    Upside

    0.0%

    downward going graph
  • $2.20
    $5.14
    $3.65
    downward going graph

    39.73%

    Downside

    52 Weeks Volatility :57.2%

    Upside

    28.99%

    downward going graph

Returns

PeriodAc Immune SaSector (Health Care)Index (Russel 2000)
3 Months
53.15%
5.3%
0.0%
6 Months
-11.1%
6.3%
0.0%
1 Year
22.73%
9.2%
0.0%
3 Years
-51.14%
13.1%
-19.9%

Highlights

Market Capitalization
357.0M
Book Value
$1.46
Earnings Per Share (EPS)
-0.69
PEG Ratio
0.0
Wall Street Target Price
10.16
Profit Margin
0.0%
Operating Margin TTM
-379.17%
Return On Assets TTM
-20.85%
Return On Equity TTM
-36.68%
Revenue TTM
14.8M
Revenue Per Share TTM
0.17
Quarterly Revenue Growth YOY
1480000.0%
Gross Profit TTM
-56.4M
EBITDA
-54.5M
Diluted Eps TTM
-0.69
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.46
EPS Estimate Next Year
-0.11
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.22

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Ac Immune Sa(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 178.36%

Current $3.65
Target $10.16

Technicals Summary

Sell

Neutral

Buy

Ac Immune Sa is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ac Immune Sa
Ac Immune Sa
-12.17%
-11.1%
22.73%
-51.14%
-32.75%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ac Immune Sa
Ac Immune Sa
NA
NA
0.0
-0.46
-0.37
-0.21
NA
1.46
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ac Immune Sa
Ac Immune Sa
Buy
$357.0M
-32.75%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Ac Immune Sa

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.0K → 14.80M (in $), with an average increase of 100.0% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.74M → -17.86M (in $), with an average decrease of 276.5% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 41.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 244.6%

Institutional Holdings

  • Bvf Inc

    14.73%
  • Avidity Partners Management LP

    4.52%
  • BlackRock Inc

    2.57%
  • Redmile Group, LLC

    2.03%
  • Morgan Stanley - Brokerage Accounts

    1.40%
  • Wells Fargo & Co

    1.13%

Company Information

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor

Organization
Ac Immune Sa
Employees
133
CEO
Dr. Andrea Pfeifer Ph.D.
Industry
Health Technology

FAQs